Abstract
Background Oligodendroglioma (ODG) are CNS resistant tumors characterized by their unique molecular signature, namely a combined deletion of 1p and 19q simultaneously to an IDH1/2 mutation. These tumors have a more favorable clinical outcome compared to other gliomas and a long-time survival that ranges between 10-20 years. However, during the course of the disease, multiple recurrences occur and the optimal treatment at each stage of the disease remains unclear. Here we report a retrospective longitudinal observation study of 836 MRI examinations in 44 ODG patients.
Methods We quantified the volume of T2-hyperintensity to compute growth behavior in dependence of different treatment modalities, using various computational models.
Results The identified growth pattern revealed dynamic changes, which were found to be patient-specific an did not correlate with clinical parameter or therapeutic interventions. Further, we showed that, surgical resection is beneficial for overall survival regardless the WHO grad or timepoint of surgery. To improve overall survival, an extent of resection above 50% is required. Multiple resections do not generally improve overall survival, except a greater extent of resection than in previous surgeries was achieved.
Conclusions Our data aids to improve the interpretation of MRI images in clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
was not registered
Funding Statement
The authors did not receive any funding for this conduction of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate An informed consent for the scientific exploration of clinical and biological data consistent with the local ethical standards and the Declaration of Helsinki was available from all patients. The study was approved by the ethic committee University of Freiburg (protocol 472/15_160880). The methods were carried out in accordance with the approved guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
no available in preprint version
ABBREVIATIONS
- GBM
- Glioblastoma
- ODG
- Oligodendroglioma
- OA
- Oligoastrozytoma
- CNS
- Central Nervous System
- WHO
- World Health Organization
- TMZ
- Temozolomide
- PC
- Procabacine + Lomustine
- PCV
- Procabacine + Lomustine + Vincristin
